About Stephanie Price

Stephanie Price is a freelance journalist covering health and wellness and specialising in the topics of medical psychedelics and cannabis. @steph_jprice

New Parkinson’s drug shows positive results in preclinical studies

IRLAB’s drug mesdopetam has displayed antipsychotic properties in an advanced model of Parkinson’ s disease psychosis (PD-P).

Discover: - IRLAB's preclinical results from mesdopetam in an advanced preclinical model of PD-P - Mesdopetam's potential as a novel therapeutic in PD-P - The role of the dopamine D3 receptor in PD-P
By |2024-07-04T17:28:43+01:0019 March 2024|Parkinson's|

HD Immune: Developing a novel therapy for Huntington’s disease

HD Immune is developing a novel monoclonal antibody therapy for Huntington’s disease patients, aiming to interfere with disease progression and delay symptom development.

Discover: - HD Immune's aim to rid the body of mutated protein - What animal model research has demonstrated so far - HD Immune's fundraising plans to advance to clinical trials

By |2025-08-27T12:50:48+01:006 March 2024|Interviews, Insight|

Research advances in neurorehabilitation

From robotics and Virtual Reality (VR) to precision rehabilitation, NR Times speaks to Professor Stephanie Clarke of The World Federation for Neurorehabilitation (WFNR) about the latest research developments and challenges in the world of cognitive rehabilitation.

Discover: - How robotics is being utilised in neurorehabilitation - How VR is helping patients with brain reorganisation - How brain imaging can help with personalised care pathways
By |2024-07-04T17:28:46+01:0027 February 2024|Insight|

Interview: Advances and challenges in Motor Neurone Disease research 

With Motor Neurone Disease affecting more than 5,000 adults in the UK and survival rates on average of 18 months, there is an urgent need to find new treatment options. In this article, we sat down with Dr Brian Dickie, director of research development at the MND Association, which has just announced a £5 million funding injection to enable more patients take part in vital clinical trials. He shares his insights on the current state of research into MND and how the funding hopes to advance this. Unlock this article to read the full interview and learn more about: - Promising lines of investigation and potential treatment pathways for MND - How gene therapy is leading to some "never seen before" results - The role AI can play in helping to manage the condition

By |2024-07-04T17:28:48+01:007 February 2024|MND / ALS|
Go to Top